SciGen signs US$145m hep B distribution deal
10 October, 2005 by Helen SchullerSingapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
Medical Developments International appoints new CEO
10 October, 2005 by Ruth BeranMelbourne-based Medical Developments International (ASX:MVP, MDI) has appointed Dr Simon Fisher as its new CEO, starting today.
In brief: Circadian, Metabolic, Mesoblast
07 October, 2005 by Ruth BeranAfter 21 years as Circadian's (ASX:CIR) founding chairman Sir Peter Derham retired at the conclusion of the company's AGM yesterday. Circadian managing director Leon Serry said that Sir Peter was stepping down because he's now 80 years of age.
SCS signs with Chemicon
07 October, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed an exclusive agreement with Californian-based stem cells solutions provider Chemicon International, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), for the manufacture and marketing of SCS' embryonic stem (ES) cell media to the research and drug discovery market.
pSivida secures US$15m, US Medicare rebate approved
07 October, 2005 by Helen SchullerpSivida has secured US$15 million (AUD$20 million) in additional funding from a New York institutional investor to assist in the development of its platform technology BioSilicon.
In brief: NeuroSolutions, Benitec, Living Cell Technologies, Chemgenex, Life Therapeutics
06 October, 2005 by Helen Schuller and Ruth BeranUK-based NeuroSolutions, the fully owned subsidiary of NeuroDiscovery (ASX:NDL), has signed its first Australian revenue contract with Perth-based biopharmaceutical company Alzhyme. NeuroSolutions' Alzheimer models will be used to investigate the potential of three Alzhyme peptides to impede the progression of the disease.
Peptech appoints new CEO
06 October, 2005 by Ruth BeranSydney's Peptech (ASX:PTD) has appointed Dr John Chiplin as its new chief executive officer, effective January 2006.
EvoGenix to optimise proteins for GlaxoSmithKline
06 October, 2005 by Ruth BeranGlaxoSmithKline (GSK) and EvoGenix (ASX:EGX) have signed a deal to apply the antibody developer's EvoGene technology to optimise selected compounds from GSK's product pipeline.
Starpharma awarded landmark contract for VivaGel development
05 October, 2005 by Helen SchullerMelbourne drug developer Starpharma (ASX:SPL) has been awarded a US$20.3 million (AUD$26.4 million) contract from the US National Institutes of Health (NIH), for the development of its HIV preventative product VivaGel.
Prime Minister's prizes for science
05 October, 2005 by Susan WilliamsonThe annual Prime Minister's prizes for science and science teaching were awarded last night at Parliament House in Canberra.
Orbis acquires 12 per cent of Acrux
05 October, 2005 by Ruth BeranBermuda-based investment manager Orbis Mutual Funds has acquired a 12 per cent stake in Melbourne-based drug delivery company Acrux (ASX:ACR).
Resonance Health awarded WA FerriScan supply contract
04 October, 2005 by Helen Schuller and Ruth BeranResonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT), has been awarded a health supply contract from the government of Western Australia's department of health, for its FerriScan diagnostic test.
Biotech incubator seeks members
30 September, 2005 by Helen SchullerA new biotechnology incubator facility due to open in Queensland by the end of this year is calling for companies seeking mentoring and support.
Solbec granted patent
29 September, 2005 by Helen SchullerSolbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.
Phylogica patent allowed
29 September, 2005 by Ruth BeranPerth-based Phylogica (ASX:PYC) has received formal notice of allowance from the European Patent and Trademark Office for its pending patent application entitled: "Isolating biological modulators from biodiverse gene fragment libraries".
